circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Piper Sandler 33rd Annual Virtual Healthcare Conference
    Nov 22, 2021 10:00 AM EST

    Piper Sandler 33rd Annual Virtual Healthcare Conference
    Nov 22, 2021 10:00 AM EST

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Dec. 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2021 it granted stock options to purchase an aggregate of 143,500 shares of common stock to 9 new employees, whose employment commenced in November 2021 ,
Toggle Summary Cytokinetics Announces Four Presentations at the 32nd International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif. , Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one oral presentation and three poster presentations at the 32 nd International Symposium on ALS/MND taking place online from December 7 – December 10, 2021 .
Toggle Summary Cytokinetics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in a fireside chat at the Piper Sandler 33 rd Annual Virtual Healthcare Conference
Toggle Summary Cytokinetics Announces Additional Results from GALACTIC-HF Presented at American Heart Association Scientific Sessions 2021
Analysis from GALACTIC-HF Shows Treatment with Omecamtiv Mecarbil Associated with Significant Reduction in the Risk of Stroke Data on Analog to CK-3828136 Adds Preclinical Support for Cardiac Troponin Activation as Novel Mechanism to Increase Cardiac Function without Impacting Cardiac Efficiency

EVENTS

There are currently no events to display.